Intact expression status of RASSF1A in acute myeloid leukemia

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Zare Abdollahi, Davood ^a   Safari, Shamsi ^a   Movafagh, Abolfazl ^a   Ghadiani, Mojtaba ^b   Riazi Isfahani, Sahand ^a   Omrani, Mir Davood ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute myeloid leukemia; AML; Cancer; Expression; RASSF1A

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RAS ASSOCIATION DOMAIN FAMILY 1 ISOFORM A GENE; REAL TIME POLYMERASE CHAIN REACTION; ACUTE MYELOID LEUKEMIA; ALLELE; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PROMOTER REGION; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ISOPROTEIN; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ALLELES; DISEASE PROGRESSION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84887547604     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0770-x     Document Type: Article

References (23)

1. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(3):497-529. (Pubitemid 33019748)
2. Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
3. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114-28.
4. Ahn EY, et al. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res. 2013;11(7):748-58.
5. Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 2011;286(8):6253-61.
6. Tan KO, et al. MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J Biol Chem. 2001;276(4):2802-7.
7. Vos MD, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem. 2006;281(8):4557-63. (Pubitemid 43847713)
8. Deng ZH, et al. Activator protein-1 involved in growth inhibition by RASSF1A gene in the human gastric carcinoma cell line SGC7901. World J Gastroenterol. 2008;14(9):1437-43. (Pubitemid 351425228)
9. Dammann R, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315-9. (Pubitemid 30437320)
10. Agathanggelou A, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20(12):1509-18. (Pubitemid 32291201)
11. Harada K, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21(27):4345-9. (Pubitemid 34753843)
12. Wong IH, et al. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res. 2004;10(3):994-1002. (Pubitemid 38198901)
13. Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1-2):73-87. (Pubitemid 46333640)
14. Barletta E, et al. Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis. 2004;25(5):749-55. (Pubitemid 38618527)
15. Bennett JM, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-5.
16. Dastugue N, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia. 1995;9(9):1491-8.
17. Greenwood MJ, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47(7):1245-52. (Pubitemid 44269630)
18. Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003;17(12):2474-86. (Pubitemid 38072587)
19. Johan MF, et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129(1):60-5. (Pubitemid 40524052)
20. Avramouli A, et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res. 2009;33(8):1130-2.
21. Zhang H, et al. Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J. 2013;27(1):232-42.
22. Florean C, et al. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics. 2011;3(5):581-609.
23. Nakao M, et al. Epigenetic system: a pathway to malignancies and a therapeutic target. Int J Hematol. 2004;80(2):103-7. (Pubitemid 39201562)